Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

NSCLC × dacomitinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 17 Lung Neoplasms 4 Neoplasm Metastasis 2 NSCLC 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Non-small Cell Lung Cancer Metastatic 1 Brain Neoplasms 1

Interventions

osimertinib 11 Pemetrexed 10 Carboplatin 10 aflutinib 8 Gefitinib 7 Drug Therapy 7 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 pembrolizumab 4 icotinib 4 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 dacomitinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04811001 2023-02-21

CAPLAND

Fondazione Ricerca Traslazionale

Phase 2 Unknown

NSCLC

NCT04575415 2020-10-20

BELLA

Guangdong Association of Clinical Trials

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡